Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Vigil Neuroscience US92673K1088

The integration of Vigil Neuroscience into French pharmaceutical giant Sanofi has been finalized. This strategic move, which concluded in late summer 2025, provides Sanofi with full control over Vigil’s promising neurology pipeline, with a particular focus on advancing a novel Alzheimer’s disease treatment candidate.

Sanofi secured the biotechnology firm through an all-cash transaction. The deal involved a payment of $8.00 per share, valuing the total acquisition at approximately $470 million. The company’s independence formally ended with its delisting from the Nasdaq in August 2025.